

Title (en)  
HUMAN TUMOR NECROSIS FACTOR RECEPTOR-LIKE 2

Title (de)  
MENSCHLICHER TUMOR NECROSIS FAKTOR REZEPTOR ÄHNLICHER REZEPTOR 2

Title (fr)  
RECEPTEUR TR2 DU FACTEUR DE NECROSE TUMORALE CHEZ L'HOMME

Publication  
**EP 1165185 A2 20020102 (EN)**

Application  
**EP 00916583 A 20000322**

Priority

- US 0007521 W 20000322
- US 12568399 P 19990322
- US 12652299 P 19990326
- US 13516999 P 19990520
- US 14738399 P 19990806

Abstract (en)  
[origin: WO0056405A2] The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR2 receptors.

IPC 1-7  
**A61P 37/00**; A61P 35/00; A61K 39/395; A61K 38/17; A61K 45/06

IPC 8 full level  
**G01N 33/50** (2006.01); **A61K 31/713** (2006.01); **A61K 35/36** (2006.01); **A61K 38/00** (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61K 45/06** (2006.01); **A61K 48/00** (2006.01); **A61P 19/02** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 37/00** (2006.01); **A61P 37/04** (2006.01); **C07K 14/705** (2006.01); **C07K 14/715** (2006.01); **C07K 16/18** (2006.01); **C07K 16/28** (2006.01); **C12N 15/09** (2006.01); **C12P 21/08** (2006.01); **G01N 33/15** (2006.01); **G01N 33/53** (2006.01); **G01N 33/566** (2006.01); **G01N 33/577** (2006.01); **A61K 39/00** (2006.01)

CPC (source: EP)  
**A61K 39/395** (2013.01); **A61K 39/39533** (2013.01); **A61K 45/06** (2013.01); **A61P 19/02** (2018.01); **A61P 29/00** (2018.01); **A61P 35/00** (2018.01); **A61P 37/00** (2018.01); **A61P 37/04** (2018.01); **C07K 14/70578** (2013.01); **C07K 16/2878** (2013.01); **A61K 48/00** (2013.01); **A61K 2039/505** (2013.01); **C07K 2317/622** (2013.01); **C07K 2319/00** (2013.01); **C12N 2799/026** (2013.01); **Y02A 50/30** (2018.01)

C-Set (source: EP)

1. **A61K 39/39533 + A61K 39/395**
2. **A61K 39/395 + A61K 38/177**
3. **A61K 39/395 + A61K 38/13**
4. **A61K 39/395 + A61K 31/00**
5. **A61K 39/395 + A61K 38/14**
6. **A61K 39/395 + A61K 38/04**
7. **A61K 39/395 + A61K 2300/00**
8. **A61K 39/39533 + A61K 2300/00**

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)  
**WO 0056405 A2 20000928**; **WO 0056405 A3 20010104**; AU 3766700 A 20001009; CA 2365405 A1 20000928; EP 1165185 A2 20020102; JP 2002540083 A 20021126

DOCDB simple family (application)  
**US 0007521 W 20000322**; AU 3766700 A 20000322; CA 2365405 A 20000322; EP 00916583 A 20000322; JP 2000606303 A 20000322